Lundbeck, Longboard Pharmaceuticals
Lundbeck to Buy Longboard Pharma in $2.6 Billion Deal
Lundbeck A/S agreed to acquire Longboard Pharmaceuticals Inc in a $2.6 billion deal that boosts its drug pipeline for serious brain diseases.The Danish pharmaceutical company is offering shareholders $60 per share in cash for US-based Longboard,
Longboard Pharmaceuticals’ stock soars amid Lundbeck’s $2.6 billion deal to acquire the company
H. Lundbeck plans to acquire Longboard Pharmaceuticals in a $2.6 billion deal, the companies announced Monday.
Lundbeck to buy neurology-focused Longboard Pharmaceuticals in $2.6 billion deal
The Danish pharma company Lundbeck said Monday it would buy Longboard Pharmaceuticals in a deal worth $2.6 billion
Denmark's Lundbeck bets on epilepsy drug with $2.6 billion Longboard deal
The companies said Lundbeck will acquire all of Longboard's shares for $60 per share, which represents a premium of 54.2% to the stock's last close of $38.90. Longboard's lead drug candidate, bexicaserin,
Denmark's H. Lundbeck To Buy Longboard Pharmaceuticals For $60/share Cash
Danish pharmaceutical company H. Lundbeck A/S (HLUKY.PK, HLUKF.PK) and Longboard Pharmaceuticals, Inc. (LBPH), announced Monday an
Why Is Epilepsy Focused Longboard Pharmaceuticals Stock Trading Higher On Monday?
H. Lundbeck acquires Longboard Pharmaceuticals for $2.6 billion. The acquisition strengthens Lundbeck's pipeline with bexicaserin, a potential treatment for Dravet syndrome and other neurological conditions.
Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline
H. Lundbeck A/S (Lundbeck) and Longboard Pharmaceuticals, Inc (NASDAQ: LBPH) (Longboard) today announced an agreement for Lundbeck to acquire Longboard. Under the terms of the agreement, Lundbeck will commence a tender offer for all outstanding shares of Longboard common stock,
Lundbeck to buy California pharma in $2.6 billion deal
The Danish pharmaceutical company, with its US headquarters in Deerfield, is boosting its drug pipeline for serious brain diseases with this deal.
Longboard Pharmaceutical Stock Soars 51%. It’s Being Bought for $2.6 Billion.
Pharmaceutical company Lundbeck will acquire Nasdaq-listed Longboard Pharmaceutical in a $2.6 billion deal, the two companies said Monday. Denmark-listed Lundbeck will make a tender offer for all shares outstanding of Longboard common stock,
Longboard Pharmaceuticals Strikes $2.6 Billion Deal to Be Acquired by Lundbeck
Longboard Pharmaceuticals (LBPH) on Monday agreed to be acquired by Danish pharmaceutical company H. Lundbeck in a deal with an equity value of about $2.6 billion. Lundbeck will launch a tender offer to purchase all of Longboard's shares for $60 apiece in cash,
FierceBiotech5h
Lundbeck signs $2.5B check for Longboard, seeing blockbuster potential in epilepsy med
After spying blockbuster potential in Longboard Pharmaceuticals’ epilepsy med, brain disease-focused pharma Lundbeck is ...
BioPharma Dive1h
Lundbeck to buy brain drug developer Longboard for $2.6B
The deal would hand Lundbeck a treatment for a series of rare brain disorders that could, by the company's estimates, become a blockbuster product.
Longboard Pharmaceuticals' stock soars on Lundbeck’s $2.6 billion deal to acquire the company
Shares of Longboard Pharmaceuticals Inc. were soaring more than 51% on Monday after the announcement of H. Lundbeck’s $2.6 billion deal to acquire the California-based clinical-stage biopharmaceutical ...
Business Times5h
Lundbeck to buy Longboard Pharma in US$2.6 billion deal
H Lundbeck agreed to acquire Longboard Pharmaceuticals in a US$2.6 billion deal that boosts its drug pipeline for serious ...
Zacks.com on MSN4d
CRL to Aid Lundbeck's Neurological Drug Research With AI-Backed Logica
Charles River Laboratories International, Inc. CRL has entered into an agreement with H. Lundbeck A/S (Lundbeck) — a Denmark-based global pharmaceutical company focused on neurological and psychiatric ...